Introduction Table 1 . Patient characteristics Characteristics Patients, n Chemotherapy for advanced endometrial carcinoma remains ineffective. Only a minority of patients respond and the responses are generally partial and brief [1, 2] . Further studies are required to identify new chemotherapeutic agents of untested chemical configuration and noncross-resistance with commonly used drugs. Mitoxantrone, a synthetic aminoan-thraquinone whose activity appears to be mediated by intercalation into the DNA double helix, was chosen for our phase II trial in patients with advanced or recurrent adenocarcinoma of the endometrium. Mitoxantrone showed a significant activity against animal tumors [3] , it showed in vitro antitumor activity against human tumor colony-forming units [4, 5] , and it has a very acceptable toxicity observed in phase I trials [6] ,. Patients and Methods Eligible patients were required to have histologically confirmed recurrent or metastatic measurable disease, of Figo-Stage III and IV, performance status (Karnofsky > 50%), adequate hematologic function (granulocyte count > 3,000/mm3 and platelet count > 100,000 mm3), bilirubin < 1.5 mg/lOOml, SGOT < 50IU and no former treatment with anthracyclines. Mitoxantrone was given at a dose of 12mg/m2, via a 5-10min infusion (150ml, NaCl 0.9%), and repeated every 21-28 days. The dose was diminished for patients showing a granulocyte or platelet count toxicity detected in weekly blood cell counts (World Health Organization toxicity criteria), and for those with gastrointestinal toxicity [7] . Tumor responses were assessed using standard criteria for complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) [7] . Of 13 patients 9 were eval·uable for response and toxicity. Six patients had adenocarcinoma, one had adenosqua-mous carcinoma, one had clear cell carcinoma, and one had endome-trioid carcinoma. Patient characteristics are shown in table 1. Results A brief no-change status (3 months) was noted in a 64-year-old woman with upper abdominal metastasis which was followed by progression of disease under 2 further courses of therapy. 12 mg/m2 -4 (27) 11 (73) Median survival time: 4.0 months Veenhof et al. 1987 [10] 14 14 mg/m2 --1 ( 7) 13 (93) Runge et al.: Mitoxantrone in Endometrial Carcinoma 103 Short Communication/Kurzmitteilung 20 courses was once 500-1,000, 1,500-2,000 3 times, 2,000-2,500 twice, and 2,500-3,000 3 times; once the platelets count was < 100,000. Mild nausea and vomiting occurred in 2 patients. No cardiac toxicity was observed. In this study, a no-change rate of 12% (1 response among 9 patients) and progression of disease in 88% of patients was observed. Our results are similar to those of the Southwest Oncology Group [8] , where none of 15 patients with endometrial carcinoma responded, 9 having received prior doxorubicin (table 2). The results of Muss et al. [9] and Veenhof et al. [10] support these poor findings (table 2) . This indicates that mitoxantrone at this dosage is inactive as a single agent in the treatment of advanced or recurrent adeno-carcinoma of the endometrium.
